Conference Coverage (ASCO)

Oral 5'-DFUR and MPA Reduce Pain in Cancer Patients

Published in Cancer Weekly, May 31st, 1999

Oral 5'-deoxy-5-fluorouridine (5'DFUR) and medroxyprogesterone acetate (MPA) improved clinical outcomes and reduced pain in breast cancer patients with painful bone metastasis.

M. Kusama, representing colleagues from the Tokyo Medical University and the Tokyo Metropolitan Cancer Detection Center, Japan, presented clinical trial data at the 35th Annual Meeting of the American Society of Clinical Oncology, held May 15-18, 1999, in Atlanta, Georgia.

According to the researchers, there is a desperate need for therapies that will promote tumor shrinkage, reduce bone pain, and could be administered on an outpatient setting to improve the quality of life of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-05-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry